BiotechTube

Extended release injectable naltrexone (Vivitrol)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alcohol Dependence

Conditions

Alcohol Dependence

Trial Timeline

Jul 1, 2007 → Feb 1, 2010

NCT ID
NCT00620750

About Extended release injectable naltrexone (Vivitrol)

Extended release injectable naltrexone (Vivitrol) is a approved stage product being developed by Alkermes for Alcohol Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00620750. Target conditions include Alcohol Dependence.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00620750ApprovedCompleted

Competing Products

20 competing products in Alcohol Dependence

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
LY686017 + PlaceboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
69
GODEX + PlaceboCelltrionPhase 3
77
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
ASP8062 + PlaceboAstellas PharmaPhase 2
52
LY686017 + PlaceboEli LillyPhase 2
52
Mazdutide + PlaceboEli LillyPhase 2
52
opioid receptor kappa antagonistEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
LY2196044 + placeboEli LillyPhase 2
52

Other Products from Alkermes

Naltrexone for extended-release injectable suspension + Oral naltrexoneApproved
82
XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injectionApproved
82
Aripiprazole LauroxilApproved
82
VIVITROL 380 mg + PlaceboApproved
82
Aripiprazole LauroxilApproved
82